NHMRC grants stem cell licence to Sydney group
17 November, 2004 by Melissa TrudingerIVFAustralia and the Diabetes Transport Unit (DTU) at the Prince of Wales Hospital in Sydney have been granted a licence by the NHMRC to create up to six new human embryonic stem cell (hESC) lines from spare IVF embryos.
Australian group offers open access to new ES cell line
15 November, 2004 by Melissa TrudingerThe first of six human embryonic stem cell (hESC) lines to be developed by Stem Cell Sciences, Melbourne IVF and the Australian Stem Cell Centre has been produced and will be made available to researchers around the world unfettered by commercial restrictions.
Cygenics to collaborate with Peter Mac on T cell trials
10 November, 2004 by Melissa TrudingerCygenics (ASX: CYN) subsidiary Cytomatrix has entered into a collaboration with Cell Therapies, the commercial arm of the Peter MacCallum Cancer Centre's Centre for Blood Cell Therapies, to test the company's T cell production technology in human clinical trials.
AusBiotech 2004: Stem cell pioneer tells why all's well in Wales
05 November, 2004 by Melissa TrudingerOne of the leading lights of international stem cell research will be in Australia next week, as a de facto ambassador for Wales as well as to discuss his research.
Public prefers publicly-funded stem cell research
02 November, 2004 by Susan WilliamsonA survey on the public perception of stem cell research suggests that how research is funded and who conducts it are more important to individuals than religious beliefs.
Stem cell research ready to blossom: Trounson
22 October, 2004 by Melissa TrudingerAccording to eminent Australian stem cell researcher Prof Alan Trounson, stem cell science is in a great place at the moment.
Agenix gets green light for Phase II trial
18 October, 2004 by Renate KrelleSix weeks after filing 5600 pages of Investigational New Drug application for a Phase II trial of its ThrombioView blood-clot imaging technology, Agenix [ASX: AGX, NASDAQ OTC: AGXLY] has been given the go-ahead by the US Food and Drug Administration.
How Biota could benefit from flu vaccine debacle
11 October, 2004 by Graeme O'NeillAfter running out of influenza vaccines during last winter's major epidemic, the US confronts the prospect of an even more severe shortfall in the coming season.
Handle stem cells with caution: expert
30 September, 2004 by Melissa TrudingerCambridge University researcher and clinician Dr Roger Barker told delegates at this week's ComBio2004 conference in Perth to exercise caution in using stem cell therapies to treat neurodegenerative diseases like Parkinson's disease.
Hep B mutation analysis platform developed by Vic disease lab
16 September, 2004 by Melissa TrudingerThe Victorian Infectious Diseases Reference Laboratory (VIDRL) has developed a platform which analyses mutations in hepatitis B virus strains carried by patients with chronic disease, and then recommends treatments based on the virus resistance profile.
Tissue Therapies names CEO
14 September, 2004 by Renate KrelleTissue Therapies (ASX:TIS) has appointed Dr Stephen Mercer -- most recently managing director of Mercy Tissue Engineering -- as its new chief executive.
J&J warns Remicade may cause blood disorders
26 August, 2004 by Staff WritersJohnson & Johnson has added a new warning to the label for rheumatoid arthritis drug Remicade about blood disorders that sometimes were fatal, US regulators have announced.
Alchemia establishes level 1 ADR program
20 August, 2004 by Renate KrelleBrisbane biotech Alchemia (ASX: ACL) has taken the first step towards a NASDAQ listing, announcing it will be establishing a Level One American Depositary Receipt (ADR) program in coming months.
MCRI to build on CyGenics' stem cell scaffold
13 August, 2004 by Melissa TrudingerStem cell company CyGenics (ASX: CYN) will collaborate with the Murdoch Children's Research Institute to perform clinical trials demonstrating that stem cells expanded from umbilical cord blood using CyGenics subsidiary Cytomatrix's proprietary cell growth scaffold retain full functionality and effectiveness.
Vaxine wins Start grant and equity partner
12 August, 2004 by Graeme O'NeillThere’s a distinct, rosy glow on the commercial horizon for unlisted Canberra vaccine developer Vaxine, with the company winning a AUD$770,000 AusIndustry R&D Start grant to advance its new-generation hepatitis B vaccine, and bringing in an equity partner to boost its cash reserves.
